Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom
Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom
复制标题
DOI：
10.1067/mai.2002.125827
复制
发表时间：
2002-07-01
影响因子：
14.2
通讯作者：
Dubois, AEJ
中科院分区：
文献类型：
--
作者：
Elberink, JNGO;de Monchy, JGR;Dubois, AEJ
背景：毒液免疫疗法(VIT)可有效预防昆虫叮咬后的过敏反应。目的：在一项开放、随机、对照的开放试验中，比较维生素T和肾上腺素自身给药装置(EpiPen)对黄夹克蛇毒过敏患者的HRQL结果。患者接受统一、标准化的信息，这些信息具体说明了他们病情的风险以及两种治疗方案的风险和好处。结果：74例患者同意随机分组，其中36例接受维生素T治疗，38例接受EpiPen治疗。VQLQ评分平均变化1.07分(95%可信区间0.68~1.46)，差异有统计学意义(P
Background: Venom immunotherapy (VIT) is effective in preventing anaphylactic reactions after insect stings. The effect of VIT on health-related quality of life (HRQL) was studied to evaluate whether this treatment is of importance to patients.Objective: We compared HRQL outcomes measured with a disease-specific instrument (Vespid Allergy Quality-of-Life Questionnaire [VQLQ]) in patients allergic to yellow jacket venom treated with VIT or with an adrenalin self-administration device (EpiPen) in an open-label, randomized, controlled trial.Methods: Consenting patients were block randomized to either VIT or EpiPen. Patients received uniform, standardized information, which specified the risk of their condition and the risks and benefits of both treatment options. HRQL measures took place before and after 1 year of treatment with VIT or EpiPen.Results: Seventy-four patients agreed to be randomized, of whom 36 received VIT and 38 an EpiPen. The mean change in VQLQ score in the group randomized to VIT was 1.07 (95% CI, 0.68-1.46), and this improvement was statistically significant (P